Back to Search
Start Over
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer Living With HIV: A Perspective on Recent Progress and Future Needs
- Source :
- JCO Oncology Practice. 16:319-325
- Publication Year :
- 2020
- Publisher :
- American Society of Clinical Oncology (ASCO), 2020.
-
Abstract
- Recent studies have identified durable responses with the use of immune checkpoint inhibitors in patients with mismatch repair–deficient (MMR-D)/microsatellite instability–high (MSI-H) metastatic colorectal cancer (CRC). The dramatic improvement in clinical outcomes led to the US Food and Drug Administration approval of pembrolizumab, nivolumab, and nivolumab in combination with ipilimumab in metastatic patients with MSI-H/MMR-D CRC who previously experienced progression on cytotoxic therapies. In the clinical trials investigating these agents, HIV-seropositive patients were not included and therefore the clinical efficacy of these agents in patients with metastatic MSI-H/MMR-D CRC living with HIV is unclear. On the basis of growing evidence, immune checkpoint blockade therapies seem to be a safe approach in patients with well-controlled HIV infection. Research on immunotherapeutic approaches in patients living with HIV and cancer is an area of unmet medical need that can be addressed by clinical trial designs that are inclusive of patients with well-controlled seropositive HIV and trials that specifically evaluate immune therapies in patients living with HIV.
- Subjects :
- 0301 basic medicine
Oncology
medicine.medical_specialty
Colorectal cancer
HIV Infections
Ipilimumab
Pembrolizumab
03 medical and health sciences
0302 clinical medicine
Internal medicine
Humans
Medicine
Immune Checkpoint Inhibitors
Oncology (nursing)
business.industry
Health Policy
Cancer
medicine.disease
United States
digestive system diseases
Immune checkpoint
Blockade
Clinical trial
030104 developmental biology
030220 oncology & carcinogenesis
Microsatellite Instability
Nivolumab
Colorectal Neoplasms
business
medicine.drug
Subjects
Details
- ISSN :
- 26881535 and 26881527
- Volume :
- 16
- Database :
- OpenAIRE
- Journal :
- JCO Oncology Practice
- Accession number :
- edsair.doi.dedup.....bdc329a2fd27e5a7cb581f4f1ddac435